Replimune Group, Inc. (REPL): Price and Financial Metrics


Replimune Group, Inc. (REPL): $32.64

1.38 (+4.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

REPL Stock Price Chart Interactive Chart >

Price chart for REPL

REPL Price/Volume Stats

Current price $32.64 52-week high $54.85
Prev. close $31.26 52-week low $20.40
Day low $31.35 Volume 155,097
Day high $32.64 Avg. volume 336,586
50-day MA $32.28 Dividend yield N/A
200-day MA $35.75 Market Cap 1.53B

Replimune Group, Inc. (REPL) Company Bio


Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.


REPL Latest News Stream


Event/Time News Detail
Loading, please wait...

REPL Latest Social Stream


Loading social stream, please wait...

View Full REPL Social Stream

Latest REPL News From Around the Web

Below are the latest news stories about Replimune Group Inc that investors may wish to consider to help them evaluate REPL as an investment opportunity.

Replimune Group Inc (REPL): Price Now Near $30.17; Daily Chart Shows Downtrend on 50 Day Basis

It''s been a feast for bears operating on an hourly timeframe, as repl has now gone down 8 of the past 10 hours. The post Replimune Group Inc (REPL): Price Now Near $30.17; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .

ETF Daily News | August 16, 2021

We're Not Worried About Replimune Group's (NASDAQ:REPL) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | August 9, 2021

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, with full accrual for both programs expected in mid-2022

Intrado Digital Media | August 6, 2021

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

Intrado Digital Media | August 2, 2021

Replimune to Present at the William Blair Biotech Focus Conference 2021

WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.

Intrado Digital Media | July 7, 2021

Read More 'REPL' Stories Here

REPL Price Returns

1-mo 7.65%
3-mo -7.80%
6-mo -7.80%
1-year 39.73%
3-year 76.81%
5-year N/A
YTD -14.44%
2020 165.85%
2019 43.50%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7953 seconds.